XML 49 R38.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Collaboration, License, and Other Agreements - Amounts Recognized in Statement of Operations with Alnylam (Details) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Disaggregation of Revenue [Line Items]    
Research and development expenses $ (1,248.4) $ (1,101.2)
Alnylam Pharmaceuticals, Inc. Collaboration Agreement | (R&D expense)    
Disaggregation of Revenue [Line Items]    
Research and development expenses $ (17.5) $ (21.3)